Taltz vs Sotyktu
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Taltz | US Sotyktu | |
|---|---|---|
| Generic name | ixekizumab | deucravacitinib |
| Drug class | IL-17A Inhibitor (Biologic) | TYK2 Inhibitor |
| Treats | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis | Plaque psoriasis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Eli Lilly | Bristol-Myers Squibb |
| Year approved | 2016 | 2022 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $190M | $130M |
| Common side effects | Injection site reactions, Respiratory infections, Inflammatory bowel disease, Low white blood cell count | Common cold symptoms, Increased infections, Cold sores, Mouth sores |
Frequently asked questions
Is Taltz or Sotyktu better?
Neither is universally "better." Taltz (ixekizumab) and Sotyktu (deucravacitinib) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Taltz and Sotyktu?
Taltz is a IL-17A Inhibitor (Biologic) made by Eli Lilly, while Sotyktu is a TYK2 Inhibitor made by Bristol-Myers Squibb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Taltz has the larger estimated TV advertising budget of the two.